ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.
The company buys Belgium’s EsoBiotec for $425m.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
